Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circ Cardiovasc Qual Outcomes. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
PMCID: PMC2798141

JUPITER: a Few Words of Caution

Since the JUPITER trial results were released in November 2008,1 they have been applauded by various sources (the media, the medical literature, cardiology experts and health authorities) and described as a breakthrough, heralding large public health benefit and potentially dictating change in clinical practice towards the expansion of the use of statins for primary prevention. Such comments include the concept that statins should be given to everyone, regardless of their lipid levels.2, 3 Based on the results of JUPITER, an additional 19% of the United States older population (men≥50 years and women ≥60 years), or over 11 million people, may become eligible for statin therapy, bringing the proportion of older adults with indications for statin therapy to about 80%.4

JUPITER, which stands for Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin, tested the hypothesis that statin treatment may reduce vascular events in persons with elevated high-sensitivity CRP but without hyperlipidemia. The study enrolled apparently healthy people with LDL cholesterol levels of less than 130 mg per deciliter but with high-sensitivity C-reactive protein (CRP) levels of 2.0 mg or more per liter. Participants were randomly assigned to receive either rosuvastatin, 20 mg orally per day, or a placebo, and followed for cardiovascular events. The trial was planned to last four years, but it was stopped early for benefit by the data and safety monitoring board, after a median follow-up of 1.9 years.

Are the Claimed Benefits Large Enough to Advocate a Change in Clinical Practice?

The reason for the enthusiasm and early termination of JUPITER was a hazard ratio of 0.56 (95% CI, 0.46 to 0.69), translating into a 44% relative risk reduction for the primary outcome favoring statin treatment, with similar reductions in other cardiovascular endpoints. But as Dr. Hlatky cautioned, in his editorial to the JUPITER trial,5 what really matters for dictating changes in clinical practice is the absolute risk reduction. This is because the absolute benefit of the treatment must be large enough to justify its potential risks and costs. Importantly, the threshold for tolerating risks and costs are particularly low when dealing with predominantly healthy populations who have low event rates, such as the sample enrolled in JUPITER. The question therefore is: are the treatment benefits achieved in the JUPITER trial large enough to advocate an expansion in the clinical indications for statins?

JUPITER used a composite outcome as the primary outcome of this trial, a technique used to minimize the enrolled sample size and a subject of potential controversy in the medical literature, especially when including outcomes of markedly different clinical severity (e.g., arterial revascularization vs. mortality).6 The rate of the primary end point, a composite of five conditions (nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, arterial revascularization, or confirmed death from cardiovascular causes) was only 0.77% per year in the rosuvastatin arm and 1.36% in the placebo arm. These rates translate into an absolute risk reduction of about a half percentage point per year (0.59%), or 1.2% over the approximately 2-year total duration of the trial. This figure is obviously much less impressive to the casual reader than the relative risk reduction of 44%. If one considers the more important and customary outcome of major coronary events, including nonfatal or fatal myocardial infarction, the yearly rate in the two arms was 0.17% and 0.37% respectively, yielding an absolute risk reduction of only 0.20% per year. However, the corresponding relative risk reduction remained an impressive 54%. When dealing with low event rates, even a small absolute difference in rates can appear dramatic when expressed in relative terms (e.g., as a hazards ratio, or relative risk reduction).

A useful measure to assess effectiveness of health care interventions is the number needed to treat.7 This is the number of patients who need to be treated in order to prevent one additional adverse outcome, and is calculated as the inverse of the absolute risk reduction. Based on an absolute risk reduction of 0.59% per year for the primary endpoint, 169 persons need to be treated for one year to prevent one combination of clinical events measured in JUPITER. For more unambiguous major coronary events, including fatal or non-fatal myocardial infarction, 500 persons need to be treated for one year to prevent one event. These are large numbers, considering that the persons being treated were deemed to be healthy at the start of the study. Therefore, the safety and costs associated with treating such patients need to be carefully considered.

While more formal cost-effectiveness studies are needed, a preliminary estimate of the economic impact of applying JUPITER in clinical practice can be approximated. Treatment with rosuvastatin costs approximately $3.50 per day, translating into a potential cost of $638,750 per year for each major coronary event averted. Using a generic statin, which costs approximately $4 per month, this figure is lower, at $24,000 per year, but still substantial. These estimates do not include the costs of screening patients and monitoring safety. In JUPITER, approximately 80% of the people who attended the screening visit eventually did not qualify for inclusion; it follows that many people would be screened for CRP and other tests who eventually would not be treated. Assuming a CRP screening test cost of $25, an additional $62,500 would have to be spent per year for each major coronary event averted. To these costs one would have to add the costs of initial testing and monitoring for liver function as recommended before and during statin therapy, and the costs of testing for plasma glucose and glycated hemoglobin, as glycated hemoglobin and diabetes incidence were elevated in JUPITER in the rosuvastatin group. Assuming that all these tests could be done for a total of $30, this could bring the costs of screening and monitoring to >$137,000 per year for each event averted.

As an alternative to screening and prescribing medications to eligible patients, potentially safer and less costly strategies could be considered for the primary prevention of cardiovascular diseases. For example, while less than 3% of health care expenditures are currently targeted towards the amelioration of behavioral risk factors such as smoking, poor diet and physical inactivity, these factors are attributed as the principal etiology of almost 40% of deaths in the United States.8 Preventive strategies aimed at these risk factors are supported by good evidence of effectiveness9 and yield a high return on investment.10

Incidentally, a modest absolute risk reduction is not unique to JUPITER, but is a characteristic of statin trials in general. In a meta-analysis including 90,056 patients with hypercholesterolemia of whom 47% had pre-existing CHD,11 there was a 23% relative risk reduction of nonfatal or fatal myocardial infarction, but only a 2.4% absolute risk reduction over a mean of 5 years, or approximately 0.48% per year (number needed to treat: 208). Thus, on average the absolute risk reduction was higher and the number needed to treat lower in previous statin trials than in JUPITER, which is expected since JUPITER enrolled lower-risk individuals. However, the relative risk reduction was higher in JUPITER (54% versus 23%, for major coronary events). This magnitude of the relative risk reduction in JUPITER raises the possibility that the effect of statin treatment was overestimated in JUPITER.

Issues Related to Early Trial Termination

Trials stopped early for benefit can overestimate treatment effects, especially when the expected number of events is low.12, 13 Compounding this issue is the fact that details of the reasons for stopping are often not reported, and effect estimates are rarely adjusted for the number of interim analyses and decreased sample size associated with stopping early.8 Despite these issues, this practice has escalated in recent years.13 The ethical rationale for stopping a trial early is to offer the beneficial intervention to the control arm and to disseminate the new findings as early as possible. However such motivation is often not justified. The rationale would hold if, once the information was made available, patients had a greater than 50% chance (i.e., greater than their randomization probability) of receiving the intervention in clinical practice. However, this seems unlikely given known delays in dissemination and translation of new trial results into practice.14

Stopping trials early for benefit can also be ethically questionable because of reduced information on other outcomes and long-term risks that would otherwise accrue.15 Thus, ethical requirements for the risk-benefit ratio may be violated when trials are terminated early. These considerations would seem to apply to JUPITER which was stopped after only 1.9 years of the planned 4 years. In the case of JUPITER, for example, we will never know the long-term consequences of the higher glycated hemoglobin levels and incidence of diabetes that were observed in the rosuvastatin group, or the long-term effects of lowering LDL cholesterol to levels below 60 mg/dL, which were never attained in previous randomized trials. Cholesterol is a physiological molecule required for many vital processes. Long-term safety is a concern especially because randomized trials carefully screen out subjects who have comorbidities or are otherwise at risk of suffering side effects from the tested drug. This is less likely to occur in regular clinical practice. Of note, subjects with a history of diabetes, uncontrolled hypertension, renal dysfunction, cancer within 5 years and many other comorbidities were excluded from JUPITER.

Potential Role of Industry

Because JUPITER was an industry-sponsored trial, readers should be cognizant of potential marketing interests when evaluating the trial results; interests may not necessarily align with public health goals.16 The strategy of stopping the trial early and the choice of presenting relative rather than absolute effect estimates are in line with the industry goals of disseminating the results quickly and in the most favorable way, therefore maximizing potential profits, while at the same time minimizing research costs. Promoting the use of drugs for healthy people, an enormous potential market, is a powerful business strategy for pharmaceutical corporations in need of showing sustained profit growth to their share holders and seeking to extend the life of their patents. Medical professionals should be aware of the commercial implications of industry-sponsored trials, which unfortunately represent the majority of contemporary drug trials. A bias related to industry sponsorship has been previously demonstrated in the presentation of trial results.17, 18 Thus, it is imperative to carefully and critically evaluate the data generated by industry-sponsored trials, since these data remain the cornerstone of evidence-based medicine and practice guidelines.


We believe that the treatment benefits achieved in the JUPITER trial are not large enough to advocate an expansion in the clinical indications for statins. The potential implications of this trial for a change in clinical practice are further limited by a lack of information on the long-term risks and benefits of statin therapy in predominantly healthy individuals. Unfortunately, it is unlikely that we will be able to gather these data in the future. Since sponsorship of major treatment trials is almost exclusively left to the pharmaceutical industry, it is doubtful that another trial will be carried out, with sufficient sample size and proper follow-up, to study the effects of statin treatment in such healthy individuals. Perhaps the most important lesson to be learned from this trial is that extreme caution should be placed in deciding to terminate early an industry-sponsored trial, such as JUPITER. At the current status of knowledge, behavioral prevention strategies remain the best investment for the prevention of cardiovascular disease and its risk factors in predominantly healthy individuals.


We thank Dr. John Spertus for his valuable editorial suggestions.

Funding Sources

Dr. Vaccarino is supported by grant K24HL077506 from the National Institutes of Health.


All authors have read and agree to the manuscript as written.




1. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Jr, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. the JSG. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008;359:2195–2207. [PubMed]
2. Weintraub H, Gagarin D. Predicting the potential effect of JUPITER. Cardiology Today. 2008 November
3. Davis EC. Should statins be available for everyone? Los Angeles Times. 2008 December 22;
4. Spatz ES, Canavan ME, Desai MM. From Here to JUPITER: Identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2:41–48. [PubMed]
5. Hlatky MA. Expanding the Orbit of Primary Prevention -- Moving beyond JUPITER. N. Engl. J. Med. 2008;359:2280–2282. [PubMed]
6. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554–2559. [PubMed]
7. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 1988;318:1728–1733. [PubMed]
8. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–1245. [PubMed]
9. Eyre H, Kahn R, Robertson RM. Preventing Cancer, Cardiovascular Disease, and Diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Diabetes Care. 2004;27:1812–1824. [PubMed]
10. Levi J, Segal LM, Juliano C. Trust for America's Health; Prevention for a healthier America: Investments in disease prevention yield significant savings, stronger communities.
11. Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet. 2005;366:1267–1278. [PubMed]
12. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J. Clin. Epidemiol. 2008;61:241–246. [PubMed]
13. Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203–2209. [PubMed]
14. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289:1969–1975. [PubMed]
15. Mueller PS, Montori VM, Bassler D, Koenig BA, Guyatt GH. Ethical issues in stopping randomized trials early because of apparent benefit. Ann. Intern. Med. 2007;146:878–881. [PubMed]
16. Landefeld CS, Steinman MA. The neurontin legacy -- marketing through misinformation and manipulation. N. Engl. J. Med. 2009;360:103–106. [PubMed]
17. Jorgensen A, Maric K, Tendal B, Faurschou A, Gotzsche P. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions. BMC Medical Research Methodology. 2008;8:60. [PMC free article] [PubMed]
18. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921–928. [PubMed]